

# Robert P Hasserjian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6105623/publications.pdf>

Version: 2024-02-01

142  
papers

14,379  
citations

159585  
30  
h-index

22166  
113  
g-index

149  
all docs

149  
docs citations

149  
times ranked

14888  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood</i> , 2016, 127, 2391-2405.  | 1.4  | 7,429     |
| 2  | Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.  | 1.4  | 1,493     |
| 3  | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.   | 1.4  | 814       |
| 4  | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.  | 1.4  | 805       |
| 5  | Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.  | 30.7 | 372       |
| 6  | Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020, 20, 285-298.   | 28.4 | 270       |
| 7  | Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .  |      | 259       |
| 8  | Differential regulation of myeloid leukemias by the bone marrow microenvironment. <i>Nature Medicine</i> , 2013, 19, 1513-1517.  | 30.7 | 233       |
| 9  | On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. <i>Nature Biomedical Engineering</i> , 2020, 4, 394-406.   | 22.5 | 170       |
| 10 | Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , 2016, 128, 1093-1100.  | 1.4  | 126       |
| 11 | Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016, 29, 854-864. | 5.5  | 104       |
| 12 | Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. <i>Blood</i> , 2010, 115, 1985-1992.   | 1.4  | 97        |
| 13 | <i>TP53</i> mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. <i>Blood Advances</i> , 2022, 6, 2847-2853.  | 5.2  | 87        |
| 14 | Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 1729-1738.  | 1.4  | 80        |
| 15 | Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.   | 1.4  | 80        |
| 16 | Immunomodulator agent-related lymphoproliferative disorders. <i>Modern Pathology</i> , 2009, 22, 1532-1540.  | 5.5  | 74        |
| 17 | High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.   | 1.4  | 64        |
| 18 | Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2017, 102, 1352-1360.               | 3.5  | 62        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. <i>Haematologica</i> , 2014, 99, 821-829. | 3.5 | 61        |
| 20 | Diverse Clinicopathologic Features in Human Herpesvirus 8-Associated Lymphomas Lead to Diagnostic Problems. <i>American Journal of Clinical Pathology</i> , 2014, 142, 816-829.  | 0.7 | 55        |
| 21 | Diagnostic Yield of CT-Guided Percutaneous Transthoracic Needle Biopsy for Diagnosis of Anterior Mediastinal Masses. <i>American Journal of Roentgenology</i> , 2015, 205, 774-779.  | 2.2 | 54        |
| 22 | Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017, 30, 1213-1222.   | 5.5 | 52        |
| 23 | tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. <i>ELife</i> , 2018, 7, .   | 6.0 | 51        |
| 24 | Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.  | 5.5 | 50        |
| 25 | Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.   | 5.2 | 44        |
| 26 | PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , 2018, 132, 686-686.   | 1.4 | 44        |
| 27 | Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics. <i>American Journal of Clinical Pathology</i> , 2015, 144, 44-60.   | 0.7 | 43        |
| 28 | High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. <i>Modern Pathology</i> , 2015, 28, 552-563.   | 5.5 | 42        |
| 29 | Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , 2015, 13, 294.   | 4.4 | 36        |
| 30 | A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. <i>American Journal of Hematology</i> , 2018, 93, 504-510.  | 4.1 | 36        |
| 31 | Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. <i>Haematologica</i> , 2021, 106, 555-564.   | 3.5 | 34        |
| 32 | European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 1062-1067.   | 4.1 | 33        |
| 33 | Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , 2015, 28, 965-976.   | 5.5 | 31        |
| 34 | Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.   | 2.8 | 31        |
| 35 | Primary lymphoma of bone in the pediatric and young adult population. <i>Human Pathology</i> , 2017, 60, 1-10.   | 2.0 | 31        |
| 36 | Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , 2014, 124, 713-713.  | 1.4 | 31        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. <i>American Journal of Surgical Pathology</i> , 2021, 45, 895-904.   | 3.7 | 29        |
| 38 | Guiding the global evolution of cytogenetic testing for hematologic malignancies. <i>Blood</i> , 2022, 139, 2273-2284.   | 1.4 | 29        |
| 39 | PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.  | 1.4 | 28        |
| 40 | Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.  | 7.2 | 27        |
| 41 | Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020, 95, 799-808.  | 4.1 | 26        |
| 42 | Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.                          | 5.5 | 25        |
| 43 | High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. <i>Modern Pathology</i> , 2014, 27, 1447-1454.   | 5.5 | 24        |
| 44 | Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 145, 538-551.  | 0.7 | 24        |
| 45 | High <i>NPM1</i> mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 921-928.   | 4.1 | 24        |
| 46 | Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.   | 2.0 | 24        |
| 47 | Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A, YAP1 and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.   | 5.5 | 24        |
| 48 | Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. <i>Modern Pathology</i> , 2016, 29, 1221-1231.  | 5.5 | 22        |
| 49 | <i>JAK2</i> V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. <i>British Journal of Haematology</i> , 2018, 182, 78-85. | 2.5 | 22        |
| 50 | The current approach to the diagnosis of myelodysplastic syndromes†. <i>Seminars in Hematology</i> , 2019, 56, 15-21.  | 3.4 | 22        |
| 51 | Molecular testing for <i>JAK2</i> , <i>MPL</i> , and <i>CALR</i> in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2016, 91, 1277-1280.   | 4.1 | 21        |
| 52 | Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 418-422.  | 1.3 | 21        |
| 53 | Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.   | 5.5 | 21        |
| 54 | Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. <i>Journal of Pathology Informatics</i> , 2013, 4, 30.  | 1.7 | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Small cell predominant extranodal <scp>NK</scp>/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population. <i>Histopathology</i> , 2016, 69, 667-679.                                       | 2.9 | 20        |
| 56 | Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <i>Haematologica</i> , 2018, 103, 626-633.                                       | 3.5 | 20        |
| 57 | Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. <i>PLoS ONE</i> , 2019, 14, e0216810.                                 | 2.5 | 20        |
| 58 | Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. <i>Blood Advances</i> , 2019, 3, 3322-3332.   | 5.2 | 20        |
| 59 | The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. <i>Blood</i> , 2021, 138, 1870-1884.  | 1.4 | 20        |
| 60 | Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. <i>American Journal of Clinical Pathology</i> , 2017, 148, 49-57.   | 0.7 | 18        |
| 61 | Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2006, 108, 3982-3982.  | 1.4 | 18        |
| 62 | TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675.  | 1.4 | 17        |
| 63 | Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 253-261.   | 0.4 | 16        |
| 64 | A phase 1 study of the antibodyâ€“drug conjugate brentuximab vedotin with reâ€“induction chemotherapy in patients with CD30â€“expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.                         | 4.1 | 15        |
| 65 | Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.   | 1.4 | 15        |
| 66 | Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013, 122, 2823-2823.                                       | 1.4 | 15        |
| 67 | Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Surgical Pathology Clinics</i> , 2016, 9, 143-163.   | 1.7 | 14        |
| 68 | Reactive Versus Neoplastic Bone Marrow: Problems and Pitfalls. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 587-594.  | 2.5 | 14        |
| 69 | <i>JAK2</i> , <i>CALR</i> , <i>MPL</i> and <i>ASXL1</i> mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2018, 103, e63-e68.              | 3.5 | 13        |
| 70 | Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2017, 58, 569-577.   | 1.3 | 12        |
| 71 | Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. <i>Modern Pathology</i> , 2020, 33, 1135-1145. | 5.5 | 12        |
| 72 | Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells. <i>Journal of Hematopathology</i> , 2011, 4, 175-181.  | 0.4 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | <i>NPM1</i> mutation but not <i>RUNX1</i> mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. <i>American Journal of Hematology</i> , 2017, 92, E123-E124. | 4.1 | 11        |
| 74 | Diagnostic algorithm for lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1679-1696.   | 7.2 | 10        |
| 75 | Erythroleukemia and Its Differential Diagnosis. <i>Surgical Pathology Clinics</i> , 2013, 6, 641-659.   | 1.7 | 9         |
| 76 | Composite chronic myeloid leukemia and essential thrombocythemia with <i>BCR-ABL1</i> fusion and <i>CALR</i> mutation. <i>American Journal of Hematology</i> , 2019, 94, 504-505.   | 4.1 | 9         |
| 77 | How I Diagnose Low-Grade Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2020, 154, 5-14.  | 0.7 | 9         |
| 78 | Multiparametric in situ imaging of <i>NPM1</i> -mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. <i>Modern Pathology</i> , 2020, 33, 1380-1388.  | 5.5 | 9         |
| 79 | Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes ( <i>JAK2/MPL/CALR</i> ) and <i>SF3B1</i> . <i>Modern Pathology</i> , 2021, 34, 20-31.  | 5.5 | 9         |
| 80 | Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101249.  | 1.7 | 9         |
| 81 | Effect of <i>DNMT3A</i> variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. <i>Blood Advances</i> , 2021, 5, 2539-2549.  | 5.2 | 9         |
| 82 | Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 323-323.   | 1.4 | 9         |
| 83 | Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, , .                                    | 5.5 | 9         |
| 84 | Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.  | 0.8 | 8         |
| 85 | Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. <i>Haematologica</i> , 2020, 105, e221-e224.  | 3.5 | 8         |
| 86 | Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.  | 5.2 | 8         |
| 87 | Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.  | 5.5 | 8         |
| 88 | Lymph node FNA cytology: Diagnostic performance and clinical implications of proposed diagnostic categories. <i>Cancer Cytopathology</i> , 2022, 130, 144-153.  | 2.4 | 8         |
| 89 | Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle?. <i>Leukemia and Lymphoma</i> , 2015, 56, 3378-3386.  | 1.3 | 7         |
| 90 | Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. <i>Leukemia and Lymphoma</i> , 2016, 57, 812-819.  | 1.3 | 7         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. <i>Journal of Clinical Pathology</i> , 2017, 70, 109-115.                               | 2.0  | 7         |
| 92  | Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology. <i>PLoS ONE</i> , 2018, 13, e0196547.   | 2.5  | 7         |
| 93  | Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. <i>Blood</i> , 2016, 128, 753-753.                            | 1.4  | 7         |
| 94  | Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). <i>American Journal of Clinical Pathology</i> , 2017, 147, 411-419.  | 0.7  | 6         |
| 95  | Illuminating neutrophilic myeloid neoplasms. <i>Blood</i> , 2019, 134, 846-848.  | 1.4  | 6         |
| 96  | Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. <i>American Journal of Hematology</i> , 2015, 90, 529-533.   | 4.1  | 5         |
| 97  | Computer-assisted quantification of CD3+ T cells in follicular lymphoma. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 609-621.  | 1.5  | 5         |
| 98  | Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. <i>Human Pathology</i> , 2017, 68, 40-46.   | 2.0  | 5         |
| 99  | Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). <i>American Journal of Clinical Pathology</i> , 2019, 152, 302-321.   | 0.7  | 5         |
| 100 | Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. <i>American Journal of Hematology</i> , 2021, 96, E420-E423. | 4.1  | 5         |
| 101 | Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. <i>Current Opinion in Hematology</i> , 2018, 25, 120-128.  | 2.5  | 4         |
| 102 | Global Cytopathology-Hematopathology Practice Trends. <i>American Journal of Clinical Pathology</i> , 2022, 157, 196-201.  | 0.7  | 4         |
| 103 | Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive. <i>American Journal of Clinical Pathology</i> , 2022, 158, 300-310.   | 0.7  | 4         |
| 104 | Case 37-2016. <i>New England Journal of Medicine</i> , 2016, 375, 2273-2282.   | 27.0 | 3         |
| 105 | A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <i>Modern Pathology</i> , 2018, 31, 873-880.   | 5.5  | 3         |
| 106 | Premalignant Clonal Hematopoietic Proliferations. <i>American Journal of Clinical Pathology</i> , 2019, 152, 347-358.  | 0.7  | 3         |
| 107 | Characterization of applicants for residency training in pathology: Does diversity exist?. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 23-25.  | 1.3  | 3         |
| 108 | Multiorgan failure in a fatal case of autoimmune hemolytic anemia. <i>Transfusion</i> , 2021, 61, 2795-2798.   | 1.6  | 3         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. <i>American Journal of Clinical Pathology</i> , 2017, 147, aqw203.                                      | 0.7  | 2         |
| 110 | Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 328-350.                            | 3.8  | 2         |
| 111 | A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.  | 5.2  | 2         |
| 112 | Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2008, 112, 3416-3416.   | 1.4  | 2         |
| 113 | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.   | 3.7  | 2         |
| 114 | This Year's Best in Hematology Diagnosis: A New Disease Is Discovered. , 2022, 19, .  |      | 2         |
| 115 | Revealing the dark secrets of TP53-mutated AML. <i>Blood</i> , 2022, 140, 8-10.   | 1.4  | 2         |
| 116 | Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase. <i>Journal of Hematopathology</i> , 2011, 4, 81-92.   | 0.4  | 1         |
| 117 | Ocular adnexal lymphoma: long-term outcome, patterns of failure and prognostic factors in 174 patients. <i>Journal of Hematopathology</i> , 2021, 14, 41-52.  | 0.4  | 1         |
| 118 | Flow cytometry reveals the nuances of clonal haematopoiesis. <i>British Journal of Haematology</i> , 2021, 192, 949-950.  | 2.5  | 1         |
| 119 | Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway. <i>Blood</i> , 2011, 118, 1670-1670.                        | 1.4  | 1         |
| 120 | Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment. <i>Blood</i> , 2012, 120, 1245-1245.  | 1.4  | 1         |
| 121 | Cytogenetic evolution between diagnosis and relapse and impact on acute myeloid leukemia (AML) reinduction outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18509-e18509.  | 1.6  | 1         |
| 122 | Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. <i>American Journal of Clinical Pathology</i> , 2007, 127, 642-650. | 0.7  | 1         |
| 123 | Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers. <i>New England Journal of Medicine</i> , 2021, 385, 1700-1710.   | 27.0 | 1         |
| 124 | Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML. <i>Blood</i> , 2021, 138, 793-793.   | 1.4  | 1         |
| 125 | Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, , .  | 5.0  | 1         |
| 126 | Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. <i>Leukemia Research Reports</i> , 2015, 4, 28-30.  | 0.4  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106625.   | 0.8 | 0         |
| 128 | Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.. <i>Blood</i> , 2005, 106, 3290-3290.   | 1.4 | 0         |
| 129 | Precursor B Lymphoblastic Lymphoma Restricted to the Central Nervous System: A Case Report. <i>FASEB Journal</i> , 2007, 21, A391.  | 0.5 | 0         |
| 130 | Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.. <i>Blood</i> , 2009, 114, 247-247.   | 1.4 | 0         |
| 131 | Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. <i>Blood</i> , 2010, 116, 2457-2457.  | 1.4 | 0         |
| 132 | Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. <i>Blood</i> , 2012, 120, 3847-3847. | 1.4 | 0         |
| 133 | Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3925-3925.   | 1.4 | 0         |
| 134 | Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. <i>Blood</i> , 2016, 128, 2749-2749.  | 1.4 | 0         |
| 135 | TP53 Immunostaining in Double-Hit and Double-Expressing High-Grade B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1876-1876.  | 1.4 | 0         |
| 136 | Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1431-1431.  | 1.4 | 0         |
| 137 | Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. <i>Blood</i> , 2018, 132, 1491-1491.   | 1.4 | 0         |
| 138 | Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. <i>Blood</i> , 2019, 134, 1442-1442.  | 1.4 | 0         |
| 139 | Changes in ABC Transporter Expression during Hematopoiesis Cause Lineage-Biased Cytopenias in Patients Treated with Aurora Kinase Inhibitors. <i>Blood</i> , 2021, 138, 4292-4292.  | 1.4 | 0         |
| 140 | Survival of the Fittest: Hypomethylating Agent/BCL-2 Inhibitor Combination Versus Intensive Chemotherapy As Frontline Treatment for Acute Myeloid Leukemia. , 2022, 19, .   |     | 0         |
| 141 | <i>TP53</i>-mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome With Excess Blasts: Two Sides of the Same Coin?. , 2022, 19, .  |     | 0         |
| 142 | ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise. , 2022, 19, .   |     | 0         |